Hematopoietic & Systemic ARS Countermeasure Therapeutics
Commercial sector
Hematopoietic & Systemic ARS Countermeasure Therapeutics
Developers of drugs, biologics, and cell therapies intended to prevent, mitigate, or treat acute radiation syndrome—primarily the hematopoietic sub-syndrome but also gastrointestinal, pulmonary, and cutaneous injury. Includes growth factors (G-CSF, GM-CSF, TPO agonists, IL-12), TLR agonists, immunomodulators, radioprotectant/radiomitigator small molecules and peptides, and cell/tissue therapies (MSCs, banked marrow, stem-cell-derived platelets).
Companies23
Commercial products63
Technology classes8
Countries4
Patents1,084
Profiled companies
Products
- Partner Therapeutics, Inc.United States2
- Humanetics CorporationUnited States2
- SynedgenUnited States3
- Valion BioUnited States4
- Bolder BioTechnologyUnited States5
- ChromoLogicUnited States2
+ 17 more